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Background: It is estimated that 17.3 million adults suffer from Major Depressive 
Disorder (MDD) in the United States (US). Despite the availability and effectiveness of 
antidepressants, nearly one-third of Veterans were nonadherent with their antidepressant 
medication at the fourth- and twelfth-month follow-up visit. Nonadherence with a prescribed 
antidepressant medication regimen leads to poor health outcomes, exacerbates comorbidities, 
increases non-compliance with other medical interventions, and increases provider frustration.  
A literature review yielded sufficient evidence to support administration of the 
Medication Adherence Rating Scale (MARS) to assess for medication-taking behaviors to help 
improve antidepressant adherence. The self-report MARS tool was developed in 1999 and 
adapted two previous tools, the four-item Morisky Medication Adherence Questionnaire (MAQ) 
and the Drug Attitude Inventory (DAI) scale.  
Purpose: The purpose of this practice change was to implement screening with the 
MARS in adult Veterans to identify barriers to adherence to a prescribed antidepressant 
medication regimen. Clinical staff’s perceptions and attitudes with the use of the tool were 
evaluated with an anticipated outcome of 90% rate of use of the MARS. The quality 




Methods: The Plan Do Study Act (PDSA) model was used to guide the implementation 
process of using the MARS. There were six total PDSA cycles. Clinicians administered the  
MARS to Veterans who scored 5 or greater on the nine-item Patient Health Questionnaire (PHQ-
9).  At the end of each of the PDSA cycle, clinicians completed between cycle debriefing 
questions. After the sixth cycle, clinicians completed post-implementation questions. 
Results: Five clinicians participated in this practice change and completed the between 
cycle debriefing and post-implementation questions. All agreed that utilization of the MARS tool 
was beneficial in helping to increase antidepressant adherence in the Veteran population. Overall 
compliance rate of use for the MARS was 72%.  Barriers to MARS administration included time 
constraints, physical and cognitive impairments, and Veteran declination. 
Conclusion: The data from this practice change suggested that MARS administration is a 
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CHAPTER 1: INTRODUCTION 
 
Medication adherence is one of the most important factors in effectively treating 
depression among Veterans. Several studies have been conducted to assess what methods 
effectively measure medication adherence. Methods used to measure medication adherence can 
be classified dichotomously as direct or indirect. Examples of direct methods include direct 
observation of the Veteran taking the medication and lab draws such as blood or urine. Examples 
of indirect methods include pill counts, monitoring frequency of prescription refills, electronic 
medication monitoring systems, Veterans’ clinical outcomes, and administering medication 
adherence questionnaires (Moon et al., 2017).  This practice change initiative focused on  
utilization of a screening questionnaire to assess medication-taking behaviors for treatment of 
Major Depressive Disorder (MDD). 
Background 
Major Depressive Disorder: Diagnosis and Treatment 
It is estimated that 17.3 million adults suffer from Major Depressive Disorder (MDD) in 
the United States (US), representing 7.1 percent of all US adults (National Institute of Mental 
Health, 2019). For an individual to be diagnosed with MDD, at least five symptoms meeting the 
DSM-5 criteria must be met. These symptoms include depressed mood, anhedonia, problems 
with appetite, problems with sleep, psychomotor retardation/agitation, low energy, problems 
with concentration, and suicidal ideation (Table A1 in Appendix A). Additionally, symptoms 
must be present for a period of at least two weeks with either depressed mood or anhedonia 




There are three main treatment phases for individuals with MDD: acute phase lasting 12 
weeks, continuation phase lasting three-to-six months, and a maintenance phase that can last 
indefinitely (Mignon & Stahl, 2009). The National Institute of Health and Care Excellence 
(NICE) and American Psychiatric Association (APA) recommend individuals, who are taking an 
antidepressant for MDD, continue taking the antidepressant beyond six months after remission of 
symptoms to lower risk of relapse of MDD (NICE, 2018). Monitoring of medication adherence 
to an antidepressant medication regimen is important to achieve remission of symptoms. 
Medication Adherence Rating Scale 
One such adherence monitoring tool is the self-report MARS tool. The MARS tool was 
developed in 1999 adapting two previous adherence tools: the four-item Medication Adherence 
Questionnaire (MAQ) and the Drug Attitude Inventory (DAI) scale (Thompson, Kulkarni, & 
Sergejew, 2000).  The MARS scale was first validated in a research study with Veterans who had 
schizophrenia, bipolar affective disorder (BPAD), depression with psychotic features, and 
schizoaffective disorders (Thompson, Kulkarni, & Sergejew, 2000). Administration of the 
MARS allowed providers to quickly assess medication-taking behaviors in Veterans. The MARS 
tool is intended to assist providers with identification of barriers and behaviors contributing to 
nonadherence in Veterans with chronic diseases, such as psychiatric disorders.  
The MARS tool consists of ten “yes” or “no”  questions (Psychiatry & Behavioral Health 
Learning Network, 2020) (Table A2 in Appendix A). Questions one-to-four represent behaviors   
that contribute to medication adherence; questions five-to-eight represent attitudes toward taking 
medications; and questions nine and ten represent attitudes towards psychotropic medication and 
the negative side-effects associated with psychotropic use (Sowunmi & Onifade, 2019). The tool 




“yes” response for questions 7-8 (Thompson, n.d.). Scores are ranked from zero to ten. A score 
of zero is suggestive of poor likelihood of adherence whereas a score of ten is suggestive of good 
likelihood of adherence (Sowunmi & Onifade, 2019).   
Description of the Problem 
 Despite the availability and effectiveness of antidepressants, nearly one-third of U.S. 
Veterans are nonadherent with their antidepressant medication at fourth- and twelfth-month 
follow-up visits (Gerlach, Chiang, & Kales, 2019). In a local Veteran’s Affairs primary care 
clinic, there are similar significant rates of nonadherence to an antidepressant medication. 
Nonadherence with a prescribed antidepressant medication regimen leads to poor health 
outcomes, exacerbates comorbidities, increases non-adherence with other medical interventions, 
and increases provider frustration. Challenges to antidepressant adherence can be classified into 
two main categories: Veteran specific and medication specific. Examples of Veteran specific 
challenges include erroneous myths about antidepressants; forgetting to take the antidepressant; 
negative attitudes or stigma; lack of education on antidepressant use; and presence of co-
morbidities. Examples of medication specific challenges include burden of taking an additional 
pill; duration of treatment; cost of treatment; adverse drug reactions (ADRs), and side effects 
(Ho, Jacob, & Tangiisuran, 2017).  
 The Strategic Analytics for Improvement and Learning (SAILs) metrics are used for 
monitoring continuous antidepressant usage within the VA Health Care system (Veterans Health 
Affairs, 2019). The two metrics are Effective Acute Phase Treatment (measure mnemonic is 
MDD43h) and Effective Continuation Phase Treatment (measure mnemonic is MDD47h).  
MDD43 measures the percentage of Veterans on new antidepressants who are adherent for 84 




phase antidepressant treatment for six months. The antidepressant non-adherence percentage 
results from the SAILS metrics at 84 days and six months from a local VA hospital system, are 
similar to the results from the VA study conducted by Gerlach, Chiang, & Kales (2019). 
Currently, clinicians are not utilizing a screening tool to assess for medication-taking 
behaviors. A practice change in which clinical staff administers a screening tool to further assess 
factors influencing adherence will facilitate identification of barriers to compliance with the 
antidepressant medication regimen. This will allow clinical staff to more effectively develop 
individualized interventions to increase antidepressant medication adherence. 
Purpose of the Project 
 The quality improvement (QI) project proposed a practice change initiative to implement 
screening with the Medication Adherence Rating Scale (MARS) in adult U.S. Veterans to 
identify barriers to adherence to a prescribed antidepressant medication regimen. The anticipated 
primary outcomes were 90% rate of use of the MARS. In order to round out the feasibility of 
sustaining this practice change, clinical staff’s perceptions and attitudes with the use of the tool 




CHAPTER 2: REVIEW OF LITERATURE 
Literature Search Process 
The literature search process focused on two areas: (1) best evidence to support 
antidepressant nonadherence is a clinical problem and (2) best evidence to support effectiveness 
of implementation of the MARS as a screening tool to facilitate identification of barriers for 
adherence to an antidepressant medication regimen.  
Best Evidence 
Antidepressant Nonadherence 
PubMed and Cumulative Index to Nursing and Allied Health Literature (CINAHL) were 
searched for best evidence to support the clinical problem of antidepressant nonadherence. The 
search terms antidepressant nonadherence and primary care or mental health were used in 
PubMed, yielding a total of 13,480 articles. Limitations were set to include clinical trials, articles 
published within the last 10 years (January 1, 2010- February 8, 2020), and trials involving 
humans only; reducing total articles to 69.  
The CINAHL search terms were antidepressant nonadherence and mental health and 
primary care. A limitation was set to articles published within the last 10 years (January 1, 2010- 
February 8, 2020). A total of 82 articles were identified and reviewed. There were no identified 
inclusion criteria for this first review of literature. Studies written in foreign languages that could 
not be translated to  English were excluded. Of the 82 articles, four were considered as 




Implementation of MARS 
PubMed and CINAHL were searched for best evidence to support implementation of the 
MARS tool to assess medication adherence with the following search terms:  Medication 
Adherence Rating Scale, screening tool and medication compliance or adherence and mental 
health. The search yielded 143 articles. Limitations were set to human species and articles 
published within the past 20 years (January 1, 2000- February 8, 2020). With the set limitations, 
the number of articles decreased from 143 to 49. There were no identified inclusion criteria for 
this first review of literature. Studies written in foreign languages that could not be translated to 
English were excluded.  Of the 49 articles, five articles were considered as satisfactory evidence 
to support implementation of the MARS tool.  
Synthesis of Literature Search 
Melynk & Fineout-Overholt’s adaption of Guyatt & Sackett (1995) hierarchy of evidence 
for treatment outcomes was used to rate the evidence in the research studies. There are seven 
levels in the hierarchy ranging from Level I to Level VII. Research study designs that fall in 
Level I are regarded as the strongest level of evidence for treatment outcomes whereas research 
study designs that fall in Level VII are regarded as the weakest level of evidence for treatment 
outcomes (Melynk & Fineout-Overholt, 2019).  
Antidepressant Nonadherence 
Three of the four articles identified in the review of literature were Level IV articles 
(Gerlach, Chiang, & Kales, 2019; Kales et al., 2016; Serna et al., 2010) and one article (Sansone 
& Sansone, 2012) was a Level VII with respect to the rating system for hierarchy of research 




 In the three level IV articles, two of the level IV articles were prospective cohort studies 
(Gerlach, Chiang, & Kales, 2019; Kales et al., 2016) and one was a retrospective cohort study 
(Serna et al., 2010).  The three studies (Gerlach, Chiang, & Kales, 2019; Kales et al., 2016; Serna 
et al., 2010) combined included 8114 participants. In the retrospective cohort study, data was 
collected from a city-wide public health prescription database from 2003-2007 (Serna et al., 
2010) in Lleida, Spain. 
In the retrospective study, antidepressant adherence was monitored via the pharmacy 
electronic database, and defined as the number of units obtained from the pharmacy relative to 
the number of months in the observation period (Serna et al., 2010). These studies supported the 
clinical problem of antidepressant nonadherence rates with the four-month rate between 27.3% 
to 29% (Gerlach, Chiang, & Kales, 2019; Kales et al., 2016), increasing to 52% at six months 
(Sansone & Sansone, 2012).    
Strengths of these studies included large sample size (Gerlach, Chiang, & Kales, 2019; 
Kales et al., 2016; Sansone & Sansone, 2012; Serna et al., 2010), inclusion of primary care 
Veterans rather than only psychiatric Veterans (Sansone & Sansone, 2012), and very current data 
continuing to support the problem of antidepressant nonadherence (Gerlach, Chiang, & Kales, 
2019).  A limitation was the number of Level IV quality of evidence studies (Melnyk & Fineout-
Overholt, 2019). 
Implementation of MARS  
All five studies identified in the literature review were Level IV articles (Fialko et al., 
2008; Fond et al., 2017; Owie, Oluto, & James, 2018; Thompson, Kulkarni,  & Sergejew, 2000; 
Sowunmi & Onifade, 2019) with respect to the rating system for hierarchy of research evidence 




All the five studies were cross sectional studies using the MARS to measure medication 
adherence (Fialko et al., 2008; Fond et al., 2016 Owie et al., 2018; Thompson, Kulkarni,  & 
Sergejew, 2000; Sowunmi & Onifade, 2019). Between the five studies, there were a total of 1112 
participants recruited from community outpatient or inpatient settings and all participants had 
psychiatric diagnoses with symptoms of psychosis. All five studies (Fialko et al., 2008; Fond et 
al., 2017; Owie et al., 2018; Thompson & Sergejew, 2000; Sowunmi & Onifade, 2019) measured 
various psychometric properties of the MARS tool that included: validity, internal consistency, 
acceptability, and reliability. 
The MARS tool was assessed as a reliable and valid tool to evaluate medication 
adherence, specific to the psychiatric population. Internal consistency was measured through 
Cronbach’s alpha score in four of the five studies. Cronbach’s alpha scores ranged from 0.6-0.76 
(Fialko et al., 2008; Owie et al., 2018; Thompson & Sergejew, 2000; Sowunmi & Onifade, 
2019).  One study used the Kuder-Richardson formula to measure internal consistency, yielding 
a value of >0.6 (Fond et al., 2017). Additionally, one study concluded the MARS tool has an 
excellent acceptability rate and takes an average of five minutes to complete (Fond et al., 2017). 
The evidence provided in these five studies supports the use of the MARS as a valid screening 
tool to assess antidepressant adherence (Fialko et al., 2008; Fond et al., 2017; Owie et al., 2018; 
Thompson, Kulkarni,  & Sergejew, 2000; Sowunmi & Onifade, 2019). 
An identified strength from four of the five studies was the large sample size (Fialko et 
al., 2008; Fond et al., 2017; Owie et al., 2018; Sowunmi & Onifade, 2019). One study had a 
small sample size (n=66); the study conducted by the developer of the MARS tool (Thompson, 
Kulkarni,  & Sergejew, 2000).  One limitation to the study was that the population had either 




which the MARS was used in a population of individuals who were taking only antidepressants 
for just depressive symptom without the presence of psychotic symptoms. All the studies 
involved participants who were taking at least one antipsychotic and had symptoms of psychosis 
(i.e. Schizophrenia, Bipolar Affective Disorder, Depression with Psychotic Features) (Fialko et 
al., 2008; Fond et al., 2017; Owie et al., 2018; Thompson, Kulkarni,  & Sergejew, 2000; 
Sowunmi & Onifade, 2019). Another limitation was the number of Level IV quality of evidence 















CHAPTER 3: FRAMEWORK FOR PROJECT IMPLEMENTATION 
 
The Plan-Do-Study-Act (PDSA) model, which consists of four stages was chosen to guide 
the implementation process of the Doctorate of Nursing Practice (DNP) QI practice change 
(Moen, 2009; Sollecito & Johnson, 2013). The field of nursing has utilized the PDSA model 
many times for QI projects. The purpose of selecting the PDSA model as a framework is that it 
guided the QI implementation process by segregating the process into four different stages and 
allowing for multiple cycles. Furthermore, it allowed the change agent (i.e. DNP Project lead) to 
have the flexibility to re-assess the implementation process and adjust as needed.  
The PDSA model provides a cyclical and sequential process of testing and learning from 
data to improve outcomes. The planning phase involves identification of a clinical problem and 
processes required to improve the clinical problem. The doing phase involves trialing the 
proposed process change on a small scale (i.e. small clinic setting). The studying phase involves 
evaluating the process change and making modifications to the process change based on the 
evaluation of the data (i.e. provider adherence and provider satisfaction). Lastly, the acting phase 
involves testing the modified process change to improve the process (Moen, 2009).   
The PDSA is a continuous cycle in which the four stages can be repeated as many times as 
needed to achieve identified outcomes with a particular intervention. There was no evidence 
supporting the use of the MARS tool in the primary care setting to assess antidepressant 
medication adherence, therefore, this practice change initiative would benefit from check-ins to 




CHAPTER 4: DESIGN 
 
The DNP project focused on a practice change initiative for a Primary Care Mental Health 
Integration (PCMHI) clinic serving a Veteran population. The PDSA model was used to guide 
the six-week process. Between-cycle PDSA debriefings were conducted to determine if revisions 
in the implementation process were indicated. At the conclusion of implementation, a final 
debriefing was conducted to discuss implementation team members’ feedback about the 




CHAPTER 5: METHODOLOGY 
Key Stakeholders 
The implementation team members were individuals on the health care team who 
administered the tool. Five staff participated in the implementation and consisted of a social 
worker, a psychologist, two psychology fellows and a psychiatric mental health nurse 
practitioner. Meetings were held with clinic leadership (i.e. clinic director and clinic coordinator) 
and approval was obtained to proceed with the QI project (Appendix B). 
Setting and Population 
The setting for the project was a VA PCMHI clinic. The mission of the VA emphasizes 
measurement-based care and the addition of a screening tool aligned with that mission. The 
implementation team administered the MARS tool to the Veteran population who scored ≥5 on 
the 9-item Patient Health Questionnaire (PHQ-9) during a PCMHI screening appointment. 
IRB Submission 
While it is not typical that QI practice change initiatives require IRB review, this project 
was submitted to the UNC IRB for determination of whether it constituted research with human 
subjects. Approval of this project was received from the University of North Carolina 
Institutional Review Board (IRB Number 20-0867). With respect to the local Veteran Affairs 
hospital IRB process, the project did not require review or oversight from the local VA human 




deemed the project as a QI practice change initiative that did not constitute research with human 
subjects. 
Implementation Process 
The administration of the MARS tool was intended to improve identification of barriers 
to adherence with antidepressant medication regimens and improve provider satisfaction 
regarding quality of care. 
 During the planning phase for implementation of the PDSA Model, evidence was 
obtained that supported the clinical significance of antidepressant nonadherence in the primary 
care setting.  Evidence consisted of external evidence (i.e. literature review) and internal 
evidence. Internal evidence obtained from pharmacy records that track antidepressant refills, 
revealed antidepressant nonadherence remained a consistent problem. A team champion and key 
stakeholders, who expressed buy in, were identified.  The implementation team members 
received a document that described the QI project’s purpose, outcomes, and the implementation 
team member’s role during the implementation process of this practice change. Individual team 
members signed a document, and their signature constituted their consent to participate. Each 
implementation team member was provided a copy and the DNP project lead kept a copy of the 
signed document (Appendix C).  
There were a total of six weekly implementation cycles, with each cycle having an 
identified implementation team member(s) administering the MARS during certain days and 
times of the week (Appendix D). Feedback about the implementation process was elicited 
between cycles. The purpose of the scheduled feedback meetings was to discuss any barriers that 




The doing phase consisted of the implementation team administering the MARS tool to 
Veterans, during a regular scheduled clinic screening visit, who scored five or higher on the 
PHQ-9 tool. The PHQ-9 is a valid depression screening scale (Beard et al., 2016), currently 
administered by providers to all Veterans who are referred from primary care clinic for PCMHI 
screening. The implementation team member scored the completed PHQ-9 tool.  If the Veteran 
scored ≥ 5 on the PHQ-9 the implementation team member requested permission from the 
Veteran to administer the MARS tool. If the Veteran provided permission, the MARS tool was 
administered. If the Veteran declined, the MARS tool was not administered, and the 
implementation team member noted “Declined” on the document. If the Veteran scored < 5 on 
the PHQ-9, the implementation team member wrote “not applicable” on the MARS document. 
All MARS tools, including “Declined,” and “not applicable,” were collected by the DNP 
project lead.  
The studying phase consisted of between-cycle telephone or email debriefings to obtain 
feedback on what was working, as well as identification of barriers to the process of the practice 
change. Between-cycle questions (Table E1 in Appendix E) was administered to an identified 
implementation team member(s) via telephone or email on Mondays, following the Fridays when 
the cycle ended. Based on feedback obtained during the debriefings, modifications were made 
before the next cycle began to improve the process and facilitate achievement of target goal. At 
the completion of the implementation, all data was analyzed to evaluate if outcomes were met.  
The last step of the PDSA Model, is the acting phase. Problems with or barriers to the 
process were identified during between-cycle debriefings. Changes in the process were made 
based on this feedback. These improvements were made in “real time” to promote success for the 




implementation debriefing was conducted (Table E2 in Appendix E). It is in this phase the 
decision occurred whether to adopt, adjust, or abandon the practice change based on the analysis 
of the collected data. Sustainability was emphasized.  
 The start date for the project was June 1, 2020. The project occurred over a span of six 




CHAPTER 6: DATA COLLECTION 
Rate of provider adherence to administration of MARS tool was collected. Semi-
structured debriefings occurred between each PDSA cycle to assess the implementation process 
and identify necessary adjustments in the process before initiating the next cycle.  The 
debriefings consisted of established questions asked of each implementation team member 
(Table E1 in Appendix E). The questions were developed based on evidence in the literature. At 
the conclusion of the implementation, a final debriefing was conducted to evaluate the process, 
assess barriers and solutions during cycles, and to discuss implementation team members’ 
perceptions about sustainability of the practice change. Specific questions were asked regarding 
feasibility, relevance, usefulness, and timeliness of the tool (Table E2 in Appendix E). These 
questions were also developed based on evidence in the literature. Aggregate data from the 




CHAPTER 7: DATA ANALYSIS AND OUTCOMES 
Quantitative and qualitative data were collected. Descriptive statistics were used to 
analyze provider adherence rates and aggregate data from the administration of the MARS tool. 
The target rate for provider implementation of the tool was 90%. Data from the MARS tools 
were entered and analyzed using Microsoft Excel version 2007. Questions 1-10 yielded 
dichotomous categories from “yes” or “no” responses. Qualitative data obtained from the semi-
structured debriefings yielded qualitative information which was analyzed using a content 
analysis procedure (Colorado State University, 2020). The interviews were transcribed by the 
DNP project lead. Transcripts were reviewed for themes by the DNP project lead and the DNP 
project chair. The identified themes were discussed to determine congruence between both 
reviewers. 
Outcomes 
 The anticipated primary outcome for the practice change initiative was a 90% compliance 
rate for provider adherence to administration of the MARS screening tool to Veterans who 
scored ≥ 5 on the PHQ-9. The outcome of 90% rate of provider adherence, which was identified 
as a reasonable target goal, was the benchmark to determine success of the implementation.  
Additionally, feedback was obtained from the implementation team members regarding whether 








 Across the 6 cycles, there were a total of 25 Veterans eligible for MARS tool 
administration. Eighteen of the 25 Veterans had recorded PHQ-9 scores. The PHQ-9 scores 
ranged from 5 to 15, with an average score of 9.55 (SD= 2.81). The frequency of each  PHQ-9 
score is displayed below in Table 1. 
Table 1: PHQ-9 Frequencies 
PHQ Score n (%) 
5 1 (5.6%) 
6 1 (5.6%) 
7 2 (11.1%) 
8 4 (22.2%) 
9 2 (11.1%) 
10 2 (11.1%) 
11 2 (11.1%) 
13 2 (11.1%) 
14 1 (5.6%) 
15 1 (5.6%) 
 
 Adherence to Administration of the Medication Adherence Rating Scale 
 The MARS administration compliance rates, sorted by discipline, are displayed below in 
Figure 1. The compliance rate (calculation: numbers of MARS administered divided by Veterans 
eligible for MARS) delineated by disciplines is as follows: psychologist was six out of eight 
(75%), psychology fellow #1 was two out of three (66.67%), social worker was five out of seven 
(71.43%), PMHNP was one out of three (33.33%), and the psychology fellow #2 was four out of 
four (100%). The psychology fellow #2 had the highest rate at 100%. The overall compliance 
rate was 72%, with a total of 18 MARS administered out of 25. The variation in compliance rates 










 Each of the 10 questions received one point with scores ranked from 0-10. One point is 
given for each “no” response for questions 1-6 and 9,10; and 1 point for each “yes” response for 
questions 7 and 8 (Thompson, n.d.). Higher scores suggest greater adherence to the medication 
regimen. For example, a score of 0 is suggestive of poor likelihood of medication adherence, 
whereas a score of 10 is suggestive of a good likelihood of adherence (Sowunmi & Onifade, 
2019). Questions one-to-four represent behaviors that contribute to medication adherence; 
questions five-to-eight represent attitudes about taking medications; and questions nine and ten 
represent attitudes about psychotropic medication and the negative side-effects associated with 
psychotropic use (Sowunmi & Onifade, 2019).  
 While 18 MARS questionnaires were administered, six (33.3%) were missing data for at 
least one question.  Figure 2 and Figure 3 below indicates the breakdown of the “yes” and “no” 

























Figure 2: Responses from Completed MARS 
 
 
Figure 3: Responses from Incomplete MARS 
 
 
As a result of the missing data for six of the MARS, all the MARS scores were adjusted 
to percentages that were calculated as “percentage of positive responses”- higher percentages 


















































a Veteran answered 9 out of the 10 questions; therefore, the percentage of positive responses was 
calculated based on those nine answered questions. The Veteran’s MARS score was a three 
based on the nine answered questions, giving him a percentage score of 33% (3/9). Using this 
scoring method, MARS scores ranged from 20% to 100%. The most common score was 40% 
(n=3).   The percentage at each score was calculated by adding the total number at that score (i.e. 
20%, 22%, 33%, 40%, 50%, 67%, 70%, 71%, 80%, 88%, 89%, 90%, & 100%) and dividing it 
by the total number of MARS (n=18).  For example, two Veterans scored a 100% on the MARS 
based on the adjusted values: therefore 2/18= 11.10%.  The percentage of Veterans at each score 
for both completed and incomplete MARS are displayed in Figure 4 below. 
 
Figure 4: Percentage of Positive Responses 
 
 
Reasons for missing data from the six Veterans who did not complete all ten questions 
were: one Veteran could not answer questions # 7, 9, and 10 (statement(s) about side effect of 
medication) because he had only taken antibiotics. Another Veteran did not state a reason as to 













































mind and body). One Veteran stated he did not know the answer for question #5 (statement: I 
take my medication only when I am sick).  One Veteran did not answer question #6 (statement: it 
is unnatural for medication to control one’s mind and body) because he thought the question was 
vague. This Veteran’s response to the question was that it is “relative to the type of medication 
and how it affects the body.”  One Veteran did not answer questions #7 and 10 (statements about 
side effects) because he was unsure how to answer. The last Veteran did not answer question #4 
(statement asked if you feel worse as a result of taking medication) because it “depends on how I 
feel.” This same Veteran did not answer question #7 because he stated did not know how to 
answer it. 
 Figure 5 below displays results related to the likelihood of adherence based on data 
collected from the completed MARS tools. A score of five was identified as the median point. 
Veterans who scored < 5 (5/12=42%) were at high risk for lower adherence to their 
antidepressant regimen and Veterans who scored ≥ 5 (7/12=58%) had a lower risk of poor 
adherence to their antidepressant regimen. 
 




High risk for Non-Adherence (Scored <5 on MARS tool)




Qualitative data were gathered between each PDSA cycle. Previously established semi-
structured questions that were developed from the evidence were used to elicit feedback from the 
implementation team members about their perceptions of the implementation process and to 
identify any barriers they encountered. Solutions were determined for any identified barriers. At 
the conclusion of the implementation process, post-implementation semi-structured questions 
were used to facilitate debriefing of the implementation of the practice change and to discuss the 
feasibility of sustaining use of the MARS screening tool in this clinic.  
 PDSA Between Cycle Debriefing Questions 
 The purpose of the PDSA between cycle debriefings (Table E1 in Appendix E) was to 
identify barriers to implementation of the MARS tool and to discuss solutions to improve the 
practice change in real time before the start of the next cycle.  
 After the completion of cycle 1, the psychologist (team champion) suggested revising the 
electronic template to make it easier to score the MARS tool. This change was implemented 
before the start of cycle 2. The updated MARS template was emailed to all implementation team 
members. 
 After completion of cycle 2, the psychologist suggested having implementation team 
members submit the completed MARS to the DNP project lead or place them in a designated 
mailbox by the end of the week. A significant increase in tele-mental health appointments as a 
result of COVID-19, with team members teleworking, resulted in decreased ability to collect the 
completed MARS tool in person.  Furthermore, it was recommended to revise the MARS cover 
sheet to include the date and the name of the provider administering the MARS tool. Both 
changes were implemented before the start of cycle 3 and an email was sent to the 




 After completion of cycle 3, the psychologist recommended to allow the option for team 
implementation members to email the completed MARS to the DNP project lead. An email was 
sent to the implementation team members to communicate the change before the start of cycle 4. 
 After completion of cycle 4, the social worker inquired about including additional 
information such as Veteran’s thoughts and comments about the MARS tool.  The social worker 
was informed Veteran’s thoughts and comments could be included on the MARS tool. This 
information was emailed to the team implementation members before the start of cycle 5. 
 After the completion of cycle 5, the social worker cited a preference for keeping the 
MARS questions consistent with respect to the form of pronouns used in the questions. The 
MARS questions used both first and second person pronouns throughout the tool. The MARS 
tool is a standardized and validated tool that cannot be changed by an individual.  As this 
suggestion is more about personal preference than about barriers to MARS administration, the 
DNP project leader suggested the social worker could change the pronoun when asking the 
question.  The PMHNP resident suggested adding the PHQ-9 score to the MARS electronic 
template. It was explained the PHQ-9 template is already added to the Veteran’s  electronic 
record and adding the PHQ-9 score to the MARS electronic template would be redundant.  
 Post-implementation Questions 
 The purpose of the post-implementation questions (Table E2 in Appendix E) at the 
completion of the intervention were to focus on the practice change process in its entirety to include 
overall perceptions, attitudes, barriers, facilitators, and suggestions for future implications for use 
of the MARS tool in this clinic; as well as other clinics in the VA system. 
 Overall, the team members agreed the MARS tool administration was feasible and easy to 




MARS questions were relevant to the Veteran population, who were receiving mental health 
treatment. Two team members mentioned the MARS may be irrelevant to Veterans who have 
never taken and/or not currently on a psychotropic medication. Others mentioned the MARS 
questions could be modified to increase clarity and make it more generalizable.  
 All five of the team members agreed the MARS tool would be beneficial for the 
treatment of depression in the Veteran population. While all agreed on the benefits of the tool, 
two team members suggested  implementation of the MARS tool in the clinic setting be done by 
nurse care managers to assist with routine medication monitoring rather than by psychologists, 
social workers, and prescribers. One team member stated the MARs tool could serve as a “great 
starting point for discussion surrounding medication/medication adherence.” Another team 
member stated it could be beneficial to track the Veteran’s attitudes or beliefs about taking an 
antidepressant. Lastly, one team member agreed the MARS tool would allow for the clinician to 
have an idea if the Veteran will adhere to the antidepressant. Contrastingly, this same team 
member felt the MARs tool was a very subjective screening tool and sometimes a Veteran may 
answer the MARS questions based on how they perceive clinician wants the Veteran to answer 
the question. 
Emerging Themes 
 Throughout the practice change, team member’s comments were documented during 
between-cycle debriefing and post-implementation debriefing questions.  Three themes emerged 
at the conclusion of the six-week implementation period. 
 Theme one was Veteran barriers. Seven of the 25 Veterans who met criteria for MARS 
administration declined the MARS tool.  In general, refusals of administration of screening tools 




cognition concerns,  Veterans who were loquacious and using up time in the appointment, and 
lack of applicability of the MARS tool to the individual Veteran. For the seven Veterans that did 
not receive the MARS, reasons are displayed in Table 2 below. 
 
Table 2: Reasons for Non-Administration of MARS 
 
Reason n (%) 
Refused 3 (42.9%) 
Hearing/Cognition concerns 1 (14.3%) 
Not on a psychotropic 1 (14.3%) 
Not enough time     2 (28.6.3%) 
 
 Theme two was process of implementation considerations. The PDSA model allowed 
consideration of the process and changes in “real time.” Communication with implementation 
team members occurred early Monday morning before Veteran’s appointments began. It was 
during this time that feedback was elicited from team members involved in the previous week’s 
cycle. Shortly after the discussion, most suggestions were implemented. Changes made to the 
implementation process were conveyed to implementation team members via an email.  Data 
such as numbers of MARS administered vs. number of Veterans eligible and reasons why 
MARS were not administered to eligible Veterans, were collected from the implementation team 
members. 
 The third, and final theme, was making meaning of Veterans’ responses. It was frequently 
reported by implementation team members that Veterans’ comments about MARS questions 
included, inapplicability, lack of clarity for what the question(s) was asking, and lack of 
understanding about psychotropic medications. Some based their answers on previous trials of 
sleep medications (trazodone & zolpidem). Others did not answer a question because it asked 




questions because he had never taken a psychotropic and currently was taking an antibiotic.  
Team members conveyed they did not know what to document based on the Veterans’ responses; 




CHAPTER 8: DISCUSSION 
The overall outcomes of the practice change initiative in the PCMHI setting supports the 
use of the MARS as a screening tool to assess for medication-taking behaviors. Although the 
overall actual provider compliance adherence rate (72%) was lower than the targeted provider 
compliance adherence rate (90%), the compliance rate demonstrated engagement by the 
implementation team members. The integration of the MARS tool generated discussion by the 
implementation team members about medication compliance factors among the Veterans they 
treat. The consensus was adoption of the practice change initiative, administration of the MARS 
tool to eligible Veterans, was sustainable at this clinic. 
A factor that affected adherence rates was team member participation. Although all five 
team members consented to participate in the practice change, one implementation team member 
did not participate during cycle 3.  There was a miscommunication between the implementation 
team member and the DNP project leader. The implementation team member did not receive the 
reminder email about their role in cycle 3. The process was later discussed and reviewed with 
this implementation team member, who was then able to move forward with participation in 
cycles 4,5,6. Clear, effective communication was identified as a critical factor for the success of 
the practice change initiative. A strategy to help mitigate participation errors in this type of 
implementation process would be to ensure an email reply confirmation from all implementation 
team members. If no confirmation reply occurred, then an additional method of communication 




The implementation team members’ comments from the post-implementation debriefing 
suggested a high likelihood of adopting the MARS tool in the clinic setting, with the 
consideration of nurse care managers’ involvement. Monitoring a Veteran’s medication regimen 
is a component of the nurse care manager’s role; therefore, they are ideally placed to administer 
the MARS tool. Additionally, the process of screening for medication behaviors facilitates 
conversations with Veterans about their knowledge, attitude, and beliefs regarding psychotropic 
medications. Most importantly, this conversation promotes opportunities for clinicians to provide 
psychoeducation to address knowledge deficits that become apparent during the conversation. 
Barriers to the effective, sustained use of the MARS tool were identified throughout the 
implementation process. The first key point is to consider additional methods about how to 
administer the MARS tool for Veterans with hearing and cognition impairments. Provision of a 
hard copy of the MARS tool prior to or upon arrival to the clinic may improve the Veteran’s 
ability to complete the tool. This could alleviate concerns about time constraints for MARS tool 
administration during the actual appointment. If time is limited, the Veteran could complete the 
MARS tool after the appointment and email or physically mail it back to the provider. Perhaps 
nurse care managers can assist with this process of supplying a copy of the tool to the Veteran 
before/after their appointment. 
The second key point for consideration is to streamline the administration guidelines for 
the MARS tool. Rather than administering the MARS tool to all Veteran who score ≥ 5 on the 
PHQ-9, it would be helpful to inquire if the Veteran has ever taken an antidepressant or confirm 
if Veteran is currently on an antidepressant. A negative response to either question would 




Incomplete data from 6 of the 18 MARS questionnaires revealed MARS questions that 
require clarification or did not apply to this Veteran population. Of the six incomplete 
questionnaires, questions #6 (n=2), #7 (n=3), and #10 (n=2) were the most frequently left 
unanswered. Question #6 stated “Is it unnatural for my mind and body to be controlled by 
medication.” Question #7 stated “my thoughts are clearer on medication.” Question #10 stated 
“medication makes me feel tired and sluggish.” Plausible solutions include provider education 
about the outcomes of this practice change initiative to administer the MARS tool with training 
about how the provider can clarify what the Veteran does not understand in these questions.  For 
example, the Veteran may not have a history of taking a psychotropic, therefore doesn't 
understand the meaning of questions 6 and 7. The provider might ask, “Have you ever taken a 
medication for your mental health” and list names of psychotropics to help the Veteran 
understand what the question is asking. Ultimately, this difficulty with the tool may be 
effectively managed by streamlining the inclusion criteria for MARS administration to include 
Veterans who have a history of taking an antidepressant and/or are currently taking an 
antidepressant.  
Results from Figure 5 reflect 42% of Veterans who were administered the MARS tool, 
are at high risk for non-adherence with an antidepressant medication. The added benefit of the 
MARS screening tool is clinicians can pinpoint specific MARS questions to identify barrier(s) 
leading to non-adherence.  For example, if a Veteran answered yes (score=0) on question #1, “do 
you ever forget to take your medication,” the clinician can develop an intervention to assist with 







A potential barrier was the novelty of this medication adherence assessment tool within 
the clinic of this hospital system. No other clinic within the hospital utilized a medication 
adherence assessment tool, resulting in possible resistance to being the first adopters. Other 
potential barriers included perception of a lack of time to administer the tool during the 
appointment and/or a belief the tool would not be helpful for the Veteran population. These 
barriers were addressed during a scheduled team meeting. Dissemination of evidence supporting 
the significance of this clinical problem, the high rate of antidepressant nonadherence, 
psychometric properties of the MARS screening tool, and purpose of the practice change were 
discussed. Evidence supporting a high level of acceptability of the MARS tool in a clinical 
setting, combined with a completion time of less than < 5 minutes were emphasized (Fond, 
2017).  Additionally, implementation team members received a copy of the schedule outlining 
their role during each of the PDSA cycles.  
Another potential barrier to implementation of the practice change was concern for 
maintaining fidelity of the tool’s administration. A solution to alleviate concern about 
inconsistency in administration was education to each team member, one-on-one, about how and 
when to administer the MARS. A flow chart was provided to the implementation team member 
as a visual graphic for the steps in the implementation process (Appendix F).  
Limitations 
A limitation of the project included lack of precedent for implementation of a screening 
tool to assess medication-taking behaviors. No clinic in the system had an established protocol 
for this practice change initiative. The time constraints for implementation may have contributed 




be sustainable. Another limitation was that paper and electronic entry of data created additional 
workload for the implementation team members. Lastly, nurse care managers were not recruited 
to participate in this practice change initiative.  Inclusion of an additional disciplinary role may 
have helped to generate additional insights and suggestions to improve the practice change 
initiative process. 
Strengths and Facilitators 
Strengths of this practice change initiative included stakeholder investment, ease-of-use 
of the screening tool, and creation of an opportunity for the clinic to be an early adopter of a 
screening tool that may improve Veteran medication adherence.  Use of the PDSA Model 
promoted close communication with the implementation team members and quick real-time 
revisions to address barriers. Earlier, lack of precedent for implementation of a screening tool to 
assess medication-taking behaviors was identified as a limitation. On the contrary, this can be 
identified as a strength. One can argue, the practice change initiative sets a precedent for 
implementing screening tools to assess medication-taking behaviors. 
Facilitators to the project included buy-in and approval from the Director and the clinic 
coordinator of PCMHI clinic. Most importantly, a team champion was identified to help lead the 
change and assist with implementation.  The team champion had significant influence due to 
their expertise and experience in the clinic. 
Sustainability 
 Sustainability of the MARS tool utilization could enhance identification of barriers to 
adherence to a prescribed antidepressant medication regimen, as well as elicit information about 
Veterans’ perceptions and beliefs about psychotropic medications. Information from the 




data, can provide comprehensive information to address the mental health needs of the Veteran 
more adequately. Inclusion of the MARS data into the electronic health record can increase the 
accessibility of this information over the course of treatment for all providers involved in the 
Veteran’s care. Overall, this tool facilitates QI of mental health care treatment, through 
identification of barriers and development of solutions to assist with increasing antidepressant 
adherence. 
  As discussed earlier, the implementation team members’ comments from the post-
implementation debriefing suggested a high likelihood of sustainability for the use of the MARS 
tool in the clinic setting, with the consideration of nurse care management involvement. Key 
actions to assist with sustainability include dissemination of the results to both the clinic 
coordinator and the director of the PCMHI clinic. It will be important to stress to the Leadership 
Team the beneficial value, feasibility, and relevance of administrating the MARS tool to the 
Veteran population. Emphasis on incorporation of the practice change into the standard of care is 
important.  Some steps have already been taken to assist with the transition into clinical practice, 
such as creation of an electronic template for the MARS tool in the electronic documentation 
system.  Additionally, informal education sessions can be provided to new staff members, who 
are unfamiliar with utilization of the MARS tool.   
Lastly, each year at this hospital system, recognition is given to the department or clinic 
who demonstrated an effective practice change that resulted in positive outcomes for the 
Veteran.  Emphasis on the importance of the sustainability of the MARS tool can be promoted as 
a QI initiative for the PCMHI clinic to increase Veterans’ health outcomes to make this clinic 




CHAPTER 9: RECOMMENDATIONS 
As a result of the data collected from this practice change initiative, key 
recommendations were identified. The first recommendation is to expand this practice change 
initiative into other PCMHI clinics within the VA system. Replication would beneficially 
facilitate evaluation of the impact of this QI practice change initiative across a variety of clinics. 
Extension into other clinics is feasible given interest and buy-in from both the PCMHI Clinic 
Coordinator and the Clinic Director.  
The second recommendation is to consider nurse care management involvement, 
particularly during medication follow-up appointments. Administration of the MARS tool by 
nurse care managers will assist the care managers to identify barriers to nonadherence.  
Identification of these barriers can highlight the process for nurse care managers to develop 
individualized interventions that assist with increasing compliance. Through discussion 
generated by administration of the MARS tool, benefits of additional mental health interventions 
that can support medication adherence may become apparent, such a group or individual 
psychotherapy, utilization of pill boxes,  and/or pill reminder alarms on  electronic devices. 
 The last recommendation is to change the inclusive criteria of administering the MARS 
tool to Veterans who score ≥ 5 on the PHQ-9 questionnaire and have previously and/or currently 




APPENDIX A: DSM-5 CRITERIA FOR MDD & MARS QUESTIONNAIRE 
 
Table A1: DSM-5 Criteria for Major Depressive Disorder 
 
Five or more of the following symptoms are present within the past two weeks and are not related to a 
medical condition. One of the symptoms must include (1) anhedonia and/or (2) depressed mood. 
1. Depressed mood 
2. Diminished interest or pleasure in activities 
3. Significant changes in appetite or weight 
4. Problems with sleep, hypersomnia, or insomnia 
5. Psychomotor retardation or agitation 
6. Low energy or fatigue 
7. Feelings of low self-worth, or guilt 
8. Problems with concentration 
9. Recurrent passive or active suicidal ideation 
American Psychiatric Association, 2013 
Table A2: Medication Adherence Rating Scale (MARS) questions 
 
Questions  
1. Do you ever forget to take your medications? Yes/No 
2. Are you careless at times about taking your medication? Yes/No 
3. When you feel better, do you sometimes stop taking your 
medication? 
Yes/No 
4. Sometimes if you feel worse when you take your medication, do you 
stop taking it? 
Yes/No 
5. I take my medication only when I am sick Yes/No 
6. It is unnatural for my mind and body to be controlled by medication Yes/No 
7. My thoughts are clearer on medication Yes/No 
8. By staying on medication, I can prevent getting sick Yes/No 
9. I feel weird, like a ‘zombie’ on medication Yes/No 
10. Medication makes me feel tired and sluggish Yes/No 












APPENDIX C: CONSENT INFORMATION FORM FOR TEAM MEMBERS 
 
To: Implementation Team Member 
 
Re: Practice Change to Implement the Medication Adherence Rating Scale 
 
In a recent study done at three VA medical centers (Ann Arbor, Detroit, & Battle Creek, 
Michigan) nearly one-third of Veterans were nonadherent with their antidepressant at the fourth 
and twelfth-month follow-up visit. Locally, through conducted chart reviews, the findings are 
similar. Antidepressant nonadherence leads to poor healthcare outcomes. Because there is often a 
high prevalence of multiple medical comorbidities with depression, untreated depression can 
lead to non-compliance with other medical interventions. The American Psychiatric Association 
guidelines for Major Depressive Disorder recommend an individual take the antidepressant 
beyond six months after remission of symptoms to prevent relapse. 
 
Currently, clinicians at the VA clinics are not utilizing a screening tool to assess for medication-
taking behaviors. I am proposing a practice change in which clinical staff administers the 
Medication Adherence Rating Scale (MARS) to Veterans who score at least ≥ 5 on the PHQ-9 at 
their primary care appointment and are interested in taking an antidepressant. Strong evidence 
exists in the literature to support the use of the MARS tool to assess medication-taking 
behaviors.  
 
This proposed practice change will facilitate identification of barriers to adherence to an 
antidepressant medication regimen. This will allow clinical staff to develop individualized 
interventions to increase antidepressant adherence. A John Hopkins School of Public Health 
research publication about policy on risk management and healthcare, discussed findings to 
support that medication adherence not only improves healthcare outcomes but also saves billions 
of dollars. With that being said, additional potential long-term outcomes benefiting both the 
Veteran and the hospital include an overall potential decrease in costs for the Veteran and the 
hospital. 
 
The target start date for implementation is June 1, 2020 and will run until July 10, 2020. My aim 
for the practice change is to have 90% clinician utilization rate of the MARS within the inclusive 
criteria. I have secured approval from Dr. Cindy Greenlee, the clinic coordinator for PCMHI 
Clinic. 
 
I would greatly appreciate your cooperation in helping to implement this practice change. Your 
signature on this document constitutes your consent to participate. 
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APPENDIX E:  INTERVENTION DEBRIEFING QUESTIONS 
 
Table E1: Formal between cycles debriefing questions 
 
1. Overall, how did this work for you? 
2. Did administration of the MARS cause significant delays in your screening 
appointment? 
3. Did Veterans share any additional information while completing the MARS? 




Table E2: Post-Implementation debriefing questions 
 
1. How feasible was administration of the MARS in the clinical setting? 
2. Overall, how much time did it take from start to finish, administering the MARS? 
3. Do you feel the MARS is relevant to the population we are treating? 
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